Overview

TCD Followed by autoSCT for Newly Diagnosed MM Patients

Status:
Unknown status
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Multiple Myeloma is a incurable disease. Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by high dose chemotherapy with autologous stem cell transplantation and TD maintenance therapy for the patients with newly diagnosed multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
Korean Multiple Myeloma Working Party
Collaborator:
Celgene Corporation
Treatments:
Thalidomide